ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30

ENANTA PHARMACEUTICALS INC

Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$11.41+0.31 (+2.79%)

Close on Oct 19, 2026

Market cap: $331.92M
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Enanta Pharmaceuticals reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Enanta Pharmaceuticals's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Enanta Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ENTA.

Operating margin-90.0% · median -44.0%

Net margin-96.9% · median -24.5%

Company	Revenue	Growth
SEPN	$98.88M	+13520.1%
ASMB	$74.85M	+125.1%
ENTA	$65.26M	–
XLO	$64.09M	+327.3%
TNGX	$53.81M	+121.5%
VTVT	$36.84M	+216600.0%

Company

Next earnings (est.): Nov 16, 2026, during market hours
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: September 30
Employees: 120
Held by institutions: 93.6%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1177648

Advertisement
300 × 250